Procoralan was expanded in the health insurance benefit while Entresto created a new paradigm by FDA approval
- ‘Procoralan(generic name: ivabradine)’ meets a new era by expansion of the health insurance benefit
Procoralan(Servier Korea, generic name: ivabradine) was first approved as a ‘chronic stable angina’ treatment in 2009, acquired approval for its effectiveness in ‘chronic cardiac insufficiency’ ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
